Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KNT-0916 in Advanced Solid Tumors With FGFR2 Alterations
NCT06800196Phase 1Recruiting
- Sponsor
- KinoTeck Therapeutics Co., Ltd
- Start
- Apr 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KNT-0916 in solid tumor (2 arms), sponsored by KinoTeck Therapeutics Co., Ltd. Primary endpoints: Dose-limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 12 months and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
KNT-0916
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06800196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800196.